Facts and hopes in immunotherapy for early-stage triple-negative breast cancer.

Abstract

A substantial fraction of early-stage triple-negative breast cancer (eTNBC) is characterized by high levels of stromal tumor-infiltrating lymphocytes (sTILs) and has a good prognosis even without systemic treatment, highlighting the importance of an endogenous anti-cancer immune response. Still, a considerable proportion of patients with eTNBC needs some 'therapeutical push' to kick-start this immune response. Exploiting this immune response with immune checkpoint inhibition (ICI), in combination with chemotherapy, has made its way into standard-of-care in eTNBC. Major challenges in the near future include finding those patients with eTNBC that can be treated with ICI alone or with a reduced chemotherapy backbone. Exploring the optimal duration of ICI and finding biomarkers to predict response will be key to enable personalized implementation of ICI in patients with eTNBC. For patients that currently do not respond effectively to ICI plus chemotherapy, challenges lie in finding new immunomodulatory therapies and develop response-guided neoadjuvant approaches.

More about this publication

Clinical cancer research : an official journal of the American Association for Cancer Research
  • Publication date 09-01-2023

This site uses cookies

This website uses cookies to ensure you get the best experience on our website.